Skip to main content

Table 1 Patient characteristics for patients with and without Non-tuberculous mycobacteria (NTM) cultured from their sputum during the study period

From: Prevalence and factors associated with nontuberculous mycobacteria in non-cystic fibrosis bronchiectasis: a multicenter observational study

Variable

NTM positive

NTM negative

p-value

(n = 18)

(n = 200)

Age, yra

64 (13.3)

54.9 (15.9)

0.02

Age ≥ 50 years

15 (83.3 %)

126 (63 %)

0.06

Gender (% females)b

78 %

60 %

0.2

BMI, kg/m2 a

23.5 (4.8)

24.9 (4.6)

0.24

BMI ≤ 23 kg/m2 b

11 (61.1 %)

65 (32.5 %)

0.034

Idiopathic

5 (27.8 %)

60 (30 %)

0.79

Post-infection

6 (33.3 %)

72 (36 %)

Systemic diseases

4 (22.2 %)

24 (12 %)

Immunodeficiency

1 (5.6 %)

4 (2 %)

COPD

2 (11.1 %)

28 (14 %)

Ciliary dyskinesia

0

7 (3.3 %)

Other

0

5 (2.5 %)

Smoking history (pack-years)c

22.2 (33)

11.6 (25.6)

0.2

Dyspnea (mMRC)

1.29 (1.3)

1.33 (1.13)

0.8

Macroscopic appearance of sputum (muco-purulent or purulent)a

7 (39 %)

125 (62.5 %)

0.045

Cystic bronchiectasisb

4 (22 %)

52 (26 %)

0.7

Number of affected lobesa

2.9 (1.3)

2.6 (1.2)

0.2

FVC, % predicteda

82.5 (23)

73.5 (24)

0.09

FVC ≥ 75 % predictedb

14 (77.8 %)

94 (47 %)

0.011

FEV1, % predicteda

72.3 (26)

63 (25)

0.15

Chronic P. aeruginosa infectionb

5 (28 %)

88 (44 %)

0.1

Chronic H. influenzae infectionb

2 (11 %)

46 (23 %)

0.1

Chronic bacterial infection, other PPMsb

2 (12 %)

90 (45 %)

0.05

Isolation of Aspergillus sppb

7 (39 %)

52 (26 %)

0.2

Macrolides (chronic use)b

3 (17 %)

22 (11 %)

0.4

Antibiotics (chronic use)b

4 (22 %)

70 (35 %)

0.2

Systemic steroids (chronic use)

1 (6 %)

8 (4 %)

0.6

Hospital admissionsc

0.5 (0.7)

0.7 (1.1)

0.5

Exacerbationsc

2.18 (1.7)

3 (2.1)

0.2

  1. BMI body mass index, COPD chronic obstructive lung disease, mMRC modified Medical Research Council, PPMs potentially pathogenic microorganisms
  2. aExpressed as mean (SD)
  3. bExpressed as frequency, number (%)
  4. cExpressed as median (IQR)